Table 1.
Inhibitor | Structure | Route | Phase | Company |
---|---|---|---|---|
Tanespimycin (17-AAG) | i.v. | III | BMS Kosan | |
Retaspimycin hydrochloride (IPI-504) | i.v. | II | Infinity | |
IPI-493 | oral | I | Infinity | |
SNX-5422 mesylate | oral | I | Pfizer Serenex, Inc. | |
AUY922 | i.v. | I/II | Novartis | |
BIIB021 CNF-2024 | oral | II | Biogen Idec | |
BIIB028 | Small molecule* | i.v. | I | Biogen Idec |
STA-9090 | Resorcinol derivative* | i.v. | I/II | Synta |
KW-2478 | Small molecule* | i.v. | I | Kyowa Hakko Kirin |
AT13387 | Small molecule* | oral, i.v. | I | Astex Therapeutics |
XL888 | Small molecule* | oral | I | Exelixis |
HSP990 | Small molecule* | oral | I | Novartis |
MPC-3100 | Small molecule* | oral | I | Myriad Pharmaceuticals |
ABI-010 | Nanoparticle albumin-bound 17-AAG | i.v. | I | Abraxis Bioscience |
The structures are not reported.